Australia markets closed

Optimi Health Corp (8BN.BE)

Berlin - Berlin Delayed price. Currency in EUR
Add to watchlist
0.1770-0.0030 (-1.67%)
As of 12:18PM CEST. Market open.
Full screen
Previous close0.1800
Open0.1770
Bid0.1430 x N/A
Ask0.2120 x N/A
Day's range0.1770 - 0.1780
52-week range0.1010 - 0.3000
Volume100
Avg. volume0
Market capN/A
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
All
News
  • GlobeNewswire

    Optimi Health Achieves Milestone: Completes In-House Production of MDMA Active Pharmaceutical Ingredient (API)

    Three batches tested and validated by third-party laboratoryVANCOUVER, British Columbia, April 15, 2024 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a leading Health Canada licensed psychedelics pharmaceutical manufacturer, specializing in controlled substances such as natural psilocybin and MDMA, has announced the completion of three batches of its MDMA Active Pharmaceutical Ingredient (API) manufactured from raw materials under the Company’s Precursor Licence.

  • GlobeNewswire

    Optimi Health Signs Psilocybin Supply Agreement With New Zealand-Based Mātai Medical Research Institute

    VANCOUVER, British Columbia, April 09, 2024 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a leading Health Canada licensed psychedelics pharmaceutical manufacturer, specializing in controlled substances such as natural psilocybin and MDMA, is proud to announce the signing of an international natural psilocybin supply agreement with New Zealand-Based Mātai Medical Research Institute (Mātai), on behalf of the Tū Wairua Project. This agreement marks Optimi's first s

  • GlobeNewswire

    Optimi Health Receives Finished Product Test Results and Certificate Of Analysis for GMP Natural Psilocybin Extract

    Company has also completed the in-house encapsulation of 5mg & 10mg psilocybin extract dosage formatsVANCOUVER, British Columbia, April 02, 2024 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a leading Health Canada licensed psychedelics pharmaceutical manufacturer, specializing in controlled substances such as natural psilocybin and MDMA, is pleased to announce that three validation batches of its Natural Psilocybin Extract have undergone full release testing and